Nath Bio-Genes (India) Ltd. (IN:NATHBIOGEN)
:NATHBIOGEN
Want to see IN:NATHBIOGEN full AI Analyst Report?
Top Page
Nath Bio-Genes (India) Ltd.
(NATHBIOGEN)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹185.00
▲(16.50% Upside)
Action:Reiterated
Date:05/11/26
The score is driven primarily by financial quality that is held back by weak and volatile cash flow (negative operating/free cash flow in 2026) despite generally profitable operations and low leverage. Valuation is a key offset with a very low P/E, while technicals are mildly supportive with the stock above key moving averages but only moderate momentum.
Positive Factors
Conservative Balance Sheet
The company's low debt-to-equity (~0.16–0.19) and steadily building equity indicate durable financial flexibility. Low leverage supports capital allocation for R&D, seasonal working capital, and weathering poor harvest cycles without forcing dilutive financing, preserving long-term strategic optionality.
Negative Factors
Weak Cash Generation
Negative operating and free cash flow despite accounting profits signals weak cash conversion, likely from working-capital swings or timing of collections/payments. This reduces near-term self-funding for seed production cycles, increases reliance on external financing, and raises execution risk across seasons.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
The company's low debt-to-equity (~0.16–0.19) and steadily building equity indicate durable financial flexibility. Low leverage supports capital allocation for R&D, seasonal working capital, and weathering poor harvest cycles without forcing dilutive financing, preserving long-term strategic optionality.
Read all positive factors
Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.26B
Dividend Yield1.26%
Average Volume (3M)2.58K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth21.98%
EPS Growth5.46%
CountryIN
Employees423
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)21.68
Shares Outstanding19,004,000
10 Day Avg. Volume2,256
30 Day Avg. Volume2,581
Financial Highlights & Ratios
PEG Ratio1.86
Price to Book (P/B)0.38
Price to Sales (P/S)0.58
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model
Company Description
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cere...
How the Company Makes Money
Nath Bio-Genes primarily makes money by selling seeds. Its core revenue stream is the sale of hybrid and improved seeds (typically sold as packaged, branded seed products) to farmers, dealers, and distributors. Revenue is generated from (a) commer...
Nath Bio-Genes (India) Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
78
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.16B | 4.45B | 3.65B | 2.48B | 3.01B | 2.78B |
| Gross Profit | 2.18B | 2.04B | 2.29B | 1.03B | 1.67B | 1.54B |
| EBITDA | 629.40M | 524.39M | 497.98M | 536.39M | 488.91M | -497.06M |
| Net Income | 462.29M | 416.30M | 386.00M | 396.19M | 350.11M | -673.38M |
Balance Sheet | ||||||
| Total Assets | 10.14B | 10.97B | 10.26B | 8.80B | 7.93B | 7.42B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 759.95M | 888.99M | 774.10M | 379.90M | 41.68M |
| Total Debt | 1.55B | 1.39B | 1.23B | 1.10B | 1.05B | 929.59M |
| Total Liabilities | 3.34B | 4.17B | 3.82B | 2.70B | 2.20B | 2.00B |
| Stockholders Equity | 6.80B | 6.80B | 6.44B | 6.10B | 5.73B | 5.42B |
Cash Flow | ||||||
| Free Cash Flow | -1.10B | -250.40M | 96.61M | 478.18M | 358.18M | -39.70M |
| Operating Cash Flow | -1.09B | -220.35M | 175.81M | 745.94M | 383.67M | 170.46M |
| Investing Cash Flow | -11.48M | -30.69M | -39.62M | -274.01M | -28.84M | -198.66M |
| Financing Cash Flow | 216.74M | 122.00M | -21.30M | -77.78M | -16.68M | -222.27M |
Nath Bio-Genes (India) Ltd. Technical Analysis
Positive
158.80
Price Trends
157.85
Positive
153.72
Positive
160.38
Positive
Market Momentum
1.15
Positive
55.89
Neutral
66.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 158.8 is below the 20-day moving average (MA) of 170.99, above the 50-day MA of 157.85, and below the 200-day MA of 160.38, indicating a bullish trend. The MACD of 1.15 indicates Positive momentum. The RSI at 55.89 is Neutral, neither overbought nor oversold. The STOCH value of 66.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.
Nath Bio-Genes (India) Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹80.61B | 6.16 | ― | 1.02% | 21.94% | 123.70% | |
71 Outperform | ₹53.38B | 14.10 | ― | 0.17% | -0.75% | -2.74% | |
66 Neutral | ₹3.26B | -40.95 | ― | 1.26% | 21.98% | 5.46% | |
64 Neutral | ₹49.22B | -69.07 | ― | 0.92% | 8.79% | 46.91% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | ₹21.80B | 49.77 | ― | 0.71% | 8.29% | 5.97% | |
56 Neutral | ₹19.03B | 21.94 | ― | 0.43% | 33.50% | 77.45% |
* Consumer Defensive Sector Average
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
171.70
-20.88
-10.84%
IN:DHANUKA
Dhanuka Agritech Limited
1,171.15
-492.62
-29.61%
IN:INSECTICID
Insecticides (India) Limited
749.30
-39.83
-5.05%
IN:IPL
India Pesticides Ltd.
165.20
-5.74
-3.36%
IN:RALLIS
Rallis India Limited
253.10
-26.56
-9.50%
IN:SHARDACROP
Sharda Cropchem Ltd.
893.50
243.90
37.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.